Estrella Immunopharma (ESLA) Profit After Tax (2021 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Profit After Tax of -$2.3 million for Q1 2026, down 8.92% year-over-year from -$2.5 million in Q1 2025, and down 273.8% quarter-over-quarter from -$613174.0 in Q4 2025.
Estrella Immunopharma (ESLA) Profit After Tax (2021 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Profit After Tax for 6 consecutive years, with -$2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 8.92% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$13.3 million (up 29.32% YoY), while the FY2025 annual figure was -$13.1 million, down 47.65% from the prior year.
- Profit After Tax retreated to -$2.3 million in Q1 2026 per ESLA's latest filing, from -$613174.0 in the prior quarter.
- Across five years, Profit After Tax topped out at -$139329.0 in Q2 2023 and bottomed at -$8.4 million in Q1 2023.
- Historically, Profit After Tax has averaged -$3.1 million across 5 years, with a median of -$2.3 million in 2026.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 17146.89% — and 2024, when it jumped 94.4%.
- Estrella Immunopharma's Profit After Tax stood at -$5.6 million in 2022, then jumped by 81.91% to -$1.0 million in 2023, then sank by 333.76% to -$4.4 million in 2024, then jumped by 86.15% to -$613174.0 in 2025, then tumbled by 273.8% to -$2.3 million in 2026.
- Business Quant data shows ESLA's Profit After Tax at -$2.3 million in Q1 2026, -$613174.0 in Q4 2025, and -$4.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Estrella Immunopharma | 32.29 Mn | 32.14 Mn | - | -2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.31 Mn |
| Mar 31, 2026 | -2.29 Mn |
| Dec 31, 2025 | -613,174.00 |
| Sep 30, 2025 | -4.80 Mn |
| Jun 30, 2025 | -5.54 Mn |
| Mar 31, 2025 | -2.10 Mn |
| Dec 31, 2024 | -4.43 Mn |
| Sep 30, 2024 | -7.80 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -469,530.00 |
| Dec 31, 2023 | -1.02 Mn |
| Sep 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -139,329.00 |
| Mar 31, 2023 | -8.38 Mn |
| Dec 31, 2022 | -5.64 Mn |
| Sep 30, 2022 | -2.89 Mn |
| Jun 30, 2022 | -359,586.00 |
| Mar 31, 2022 | -141,252.00 |
| Dec 31, 2021 | -135,797.00 |
| Sep 30, 2021 | -107,547.00 |